RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting
<strong>Background: </strong>RH5 is the leading vaccine candidate for the Plasmodium falciparum blood stage and has shown impact on parasite growth in the blood in a human clinical trial. RH5 binds to Ripr and CyRPA at the apical end of the invasive merozoite form, and this complex, desi...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Frontiers Media
2022
|
| _version_ | 1826310752959463424 |
|---|---|
| author | Healer, J Thompson, JK Mackwell, KL Browne, CD Seager, BA Ngo, A Lowes, KN Silk, SE Pulido, D King, LDW Christen, JM Noe, AR Kotraiah, V Masendycz, PJ Rajagopalan, R Lucas, L Stanford, MM Soisson, L Diggs, C Miller, R Youll, S Wycherley, K Draper, SJ Cowman, AF |
| author_facet | Healer, J Thompson, JK Mackwell, KL Browne, CD Seager, BA Ngo, A Lowes, KN Silk, SE Pulido, D King, LDW Christen, JM Noe, AR Kotraiah, V Masendycz, PJ Rajagopalan, R Lucas, L Stanford, MM Soisson, L Diggs, C Miller, R Youll, S Wycherley, K Draper, SJ Cowman, AF |
| author_sort | Healer, J |
| collection | OXFORD |
| description | <strong>Background: </strong>RH5 is the leading vaccine candidate for the Plasmodium falciparum blood stage and has shown impact on parasite growth in the blood in a human clinical trial. RH5 binds to Ripr and CyRPA at the apical end of the invasive merozoite form, and this complex, designated RCR, is essential for entry into human erythrocytes. RH5 has advanced to human clinical trials, and the impact on parasite growth in the blood was encouraging but modest. This study assessed the potential of a protein-in-adjuvant blood stage malaria vaccine based on a combination of RH5, Ripr and CyRPA to provide improved neutralizing activity against P. falciparum in vitro.
<br><strong>
Methods: </strong>Mice were immunized with the individual RCR antigens to down select the best performing adjuvant formulation and rats were immunized with the individual RCR antigens to select the correct antigen dose. A second cohort of rats were immunized with single, double and triple antigen combinations to assess immunogenicity and parasite neutralizing activity in growth inhibition assays.
<br><strong>
Results: </strong>The DPX® platform was identified as the best performing formulation in potentiating P. falciparum inhibitory antibody responses to these antigens. The three antigens derived from RH5, Ripr and CyRPA proteins formulated with DPX induced highly inhibitory parasite neutralising antibodies. Notably, RH5 either as a single antigen or in combination with Ripr and/or CyRPA, induced inhibitory antibodies that outperformed CyRPA, Ripr.
<br><strong>
Conclusion: </strong>An RCR combination vaccine may not induce substantially improved protective immunity as compared with RH5 as a single immunogen in a clinical setting and leaves the development pathway open for other antigens to be combined with RH5 as a next generation malaria vaccine. |
| first_indexed | 2024-03-07T07:56:37Z |
| format | Journal article |
| id | oxford-uuid:d1aad7c3-0f26-4ed0-9bbf-0025c80f2f80 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:56:37Z |
| publishDate | 2022 |
| publisher | Frontiers Media |
| record_format | dspace |
| spelling | oxford-uuid:d1aad7c3-0f26-4ed0-9bbf-0025c80f2f802023-08-22T15:39:13ZRH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical settingJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d1aad7c3-0f26-4ed0-9bbf-0025c80f2f80EnglishSymplectic ElementsFrontiers Media2022Healer, JThompson, JKMackwell, KLBrowne, CDSeager, BANgo, ALowes, KNSilk, SEPulido, DKing, LDWChristen, JMNoe, ARKotraiah, VMasendycz, PJRajagopalan, RLucas, LStanford, MMSoisson, LDiggs, CMiller, RYoull, SWycherley, KDraper, SJCowman, AF<strong>Background: </strong>RH5 is the leading vaccine candidate for the Plasmodium falciparum blood stage and has shown impact on parasite growth in the blood in a human clinical trial. RH5 binds to Ripr and CyRPA at the apical end of the invasive merozoite form, and this complex, designated RCR, is essential for entry into human erythrocytes. RH5 has advanced to human clinical trials, and the impact on parasite growth in the blood was encouraging but modest. This study assessed the potential of a protein-in-adjuvant blood stage malaria vaccine based on a combination of RH5, Ripr and CyRPA to provide improved neutralizing activity against P. falciparum in vitro. <br><strong> Methods: </strong>Mice were immunized with the individual RCR antigens to down select the best performing adjuvant formulation and rats were immunized with the individual RCR antigens to select the correct antigen dose. A second cohort of rats were immunized with single, double and triple antigen combinations to assess immunogenicity and parasite neutralizing activity in growth inhibition assays. <br><strong> Results: </strong>The DPX® platform was identified as the best performing formulation in potentiating P. falciparum inhibitory antibody responses to these antigens. The three antigens derived from RH5, Ripr and CyRPA proteins formulated with DPX induced highly inhibitory parasite neutralising antibodies. Notably, RH5 either as a single antigen or in combination with Ripr and/or CyRPA, induced inhibitory antibodies that outperformed CyRPA, Ripr. <br><strong> Conclusion: </strong>An RCR combination vaccine may not induce substantially improved protective immunity as compared with RH5 as a single immunogen in a clinical setting and leaves the development pathway open for other antigens to be combined with RH5 as a next generation malaria vaccine. |
| spellingShingle | Healer, J Thompson, JK Mackwell, KL Browne, CD Seager, BA Ngo, A Lowes, KN Silk, SE Pulido, D King, LDW Christen, JM Noe, AR Kotraiah, V Masendycz, PJ Rajagopalan, R Lucas, L Stanford, MM Soisson, L Diggs, C Miller, R Youll, S Wycherley, K Draper, SJ Cowman, AF RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting |
| title | RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting |
| title_full | RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting |
| title_fullStr | RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting |
| title_full_unstemmed | RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting |
| title_short | RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting |
| title_sort | rh5 1 cyrpa ripr antigen combination vaccine shows little improvement over rh5 1 in a preclinical setting |
| work_keys_str_mv | AT healerj rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT thompsonjk rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT mackwellkl rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT brownecd rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT seagerba rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT ngoa rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT loweskn rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT silkse rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT pulidod rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT kingldw rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT christenjm rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT noear rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT kotraiahv rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT masendyczpj rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT rajagopalanr rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT lucasl rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT stanfordmm rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT soissonl rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT diggsc rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT millerr rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT youlls rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT wycherleyk rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT drapersj rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting AT cowmanaf rh51cyrpariprantigencombinationvaccineshowslittleimprovementoverrh51inapreclinicalsetting |